Top

International Journal of Clinical Oncology

Published in:

01-04-2011 | Review Article

Cryoimmunology for malignant bone and soft-tissue tumors

Authors: Hideji Nishida, Norio Yamamoto, Yoshikazu Tanzawa, Hiroyuki Tsuchiya

Published in: International Journal of Clinical Oncology | Issue 2/2011

Abstract

Several new methods have recently been developed for the treatment of malignant bone and soft-tissue tumors, and many of these targeted therapies have yielded promising initial results in clinical settings. As more sarcomas become amenable to effective molecular-targeting therapy, the need to evaluate the synergistic effects of combination therapies with anticancer drugs will grow. Other immunologic therapies have also been reported, such as exogenous cytokines, dendritic cell (DC) therapy and peptide vaccines. Cryoimmunology has shown promising results in some malignant tumors after cryosurgery and is expected to influence the next generation of tumor immunotherapy. In this report, we describe the induction of a systemic antitumor immune response following liquid nitrogen cryotreatment of a destructive murine osteosarcoma. Combining tumor cryotreatment with DCs to promote tumor-specific immune responses enhanced systemic immune responses and inhibited metastatic tumor growth. We also describe the induction of a systemic antitumor immune response following reconstruction for malignant bone tumors using frozen autografts treated with liquid nitrogen.

Bacci G, Longhi A, Versari M et al (2006) Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer 106:1154–1161PubMedCrossRef

Bielack SS, Kempf-Bielack B, Delling G et al (2002) Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20:776–790PubMedCrossRef

Meyers PA, Schwartz CL, Krailo M et al (2005) Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 23:2004–2011PubMedCrossRef

Provisor AJ, Ettinger LJ, Nachman JB et al (1997) Treatment of non-metastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children’s Cancer Group. J Clin Oncol 15:76–84PubMed

Tsuchiya H, Yasutake H, Yokogawa A et al (1992) Effect of chemotherapy combined with caffeine for osteosarcoma. J Cancer Res Clin Oncol 118:567–569PubMedCrossRef

Tsuchiya H, Tomita K, Mori Y et al (1999) Marginal excision for osteosarcoma with caffeine assisted chemotherapy. Clin Orthop Relat Res 358:27–35PubMedCrossRef

Tsuchiya H, Tomita K, Mori Y et al (1998) Caffeine-assisted chemotherapy and minimized tumor excision for non-metastatic osteosarcoma. Anticancer Res 18:657–666PubMed

Tsuchiya H, Kanazawa Y, Abdel-Wanis ME et al (2002) Effect of timing of pulmonary metastases identification on prognosis of patients with osteosarcoma: the Japanese Musculoskeletal Oncology Group study. J Clin Oncol 20:3470–3477PubMedCrossRef

Pacey S, Ratain MJ, Flaherty KT et al (2011) Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial. Invest New Drugs [Epub ahead of print]

10.

Maki RG, D’Adamo DR, Keohan ML et al (2009) Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 27:3133–3140PubMedCrossRef

11.

Kuenen BC, Tabernero J, Baselga J et al (2003) Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma. Clin Cancer Res 9:1648–1655PubMed

12.

Stopeck A, Sheldon M, Vahedian M et al (2002) Results of a phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies. Clin Cancer Res 8:2798–2805PubMed

13.

D’Adamo DR, Anderson SE, Albritton K et al (2005) Phase II study of doxorubicin and bevacizumab for patients with metastatic soft tissue sarcomas. J Clin Oncol 23:7135–7142PubMedCrossRef

14.

Fuller CK, Charlson JA, Dankle SK et al (2010) Dramatic improvement of inoperable angiosarcoma with combination paclitaxel and bevacizumab chemotherapy. J Am Acad Dermatol 63:83–84CrossRef

15.

Jordan K, Wolf HH, Voigt W et al (2010) Bevacizumab in combination with sequential high-dose chemotherapy in solid cancer, a feasibility study. Bone Marrow Transplant 45:1704–1709PubMedCrossRef

16.

Sleijfer S, Ray-Coquard I, Papai Z et al (2009) Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 27:3126–3132PubMedCrossRef

17.

Sugiura H, Fujiwara Y, Ando M et al (2010) Multicenter phase II trial assessing effectiveness of imatinib mesylate on relapsed or refractory KIT-positive or PDGFR-positive sarcoma. J Orthop Sci 15:654–660PubMedCrossRef

18.

Grignani G, Palmerini E, Stacchiotti S et al (2010) A phase 2 trial of imatinib mesylate in patients with recurrent nonresectable chondrosarcomas expressing platelet-derived growth factor receptor-α or -β: an Italian Sarcoma Group study. Cancer 117:826–831PubMedCrossRef

19.

Luksch R, Perotti D, Cefalo G et al (2003) Immunomodulation in a treatment program including pre- and post-operative interleukin-2 and chemotherapy for childhood osteosarcoma. Tumori 3:263–268

20.

Geiger J, Hutchinson R, Hohenkirk L et al (2000) Treatment of solid tumours in children with tumour-lysate-pulsed dendritic cells. Lancet 356:1163–1165PubMedCrossRef

21.

Tabarkiewicz J, Radej S, Hus I et al (2008) Dendritic cells based immunotherapy of patient with chondrosarcoma—case report. Folia Histochem Cytobiol 46:165–170PubMedCrossRef

22.

Ohta H, Hashii Y, Yoneda A et al (2009) WT1 (Wilms tumor 1) peptide immunotherapy for childhood rhabdomyosarcoma: a case report. Pediatr Hematol Oncol 26:74–83PubMedCrossRef

23.

Ayyoub M, Taub RN, Keohan ML et al (2004) The frequent expression of cancer/testis antigens provides opportunities for immunotherapeutic targeting of sarcoma. Cancer Immun 4:7PubMed

24.

Segal NH, Blachere NE, Guevara-Patino JA et al (2005) Identification of cancer-testis genes expressed by melanoma and soft tissue sarcoma using bioinformatics. Cancer Immun 5:2PubMed

25.

Mackall CL, Rhee EH, Read EJ et al (2008) A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas. Clin Cancer Res 14:4850PubMedCrossRef

26.

Gage A (1998) History of cryosurgery. Semin Surg Oncol 14:99–109PubMedCrossRef

27.

Flanders VL, Gervais DA (2010) Ablation of liver metastases: current status. J Vasc Interv Radiol 21:S214–S222PubMedCrossRef

28.

Huang A, McCall JM, Weston MD et al (2002) Phase I study of percutaneous cryotherapy for colorectal liver metastasis. Br J Surg 89:303–310PubMedCrossRef

29.

Chin JL, Lim D, Abdelhady M (2007) Review of primary and salvage cryo-ablation for prostate cancer. Cancer Control 14:231–237PubMed

30.

Atwell TD, Farrell MA, Callstrom MR et al (2007) Percutaneous cryo-ablation of large renal masses: technical feasibility and short-term outcome. AJR Am J Roentgenol 188:1195–1200PubMedCrossRef

31.

Sabel MS, Kaufman CS, Whitworth P et al (2004) Cryo-ablation of early-stage breast cancer: work-in-progress report of a multi-institutional trial. Ann Surg Oncol 11:542–549PubMedCrossRef

32.

Karlsson JO, Cravalho EG, Borel Rinkes IH et al (1993) Nucleation and growth of ice crystals inside cultured hepatocytes during freezing in the presence of dimethyl sulfoxide. Biophys J 65:2524–2536PubMedCrossRef

33.

Hoffmann NE, Bischof JC (2002) The cryobiology of cryosurgical injury. Urology 60:40–49PubMedCrossRef

34.

Sidana A, Chowdhury WH, Fuchs EJ et al (2010) Cryoimmunotherapy in urologic oncology. Urology 75:1009–1014PubMedCrossRef

35.

Marcove RC, Miller TR, Cahan WC et al (1968) The treatment of primary and metastatic bone tumors by repetitive freezing. Acad Med 44:532–544

36.

Biesecker JL, Marcove RC, Huvos AG et al (1970) Aneurysmal bone cysts. A clinicopathologic study of 66 cases. Cancer 26:615–625PubMedCrossRef

37.

Marcove RC, Weis LD, Vaghaiwalla MR et al (1978) Cryosurgery in the treatment of giant cell tumors of bone. A report of 52 consecutive cases. Cancer 41:957–969PubMedCrossRef

38.

Huvos AG, Marcove RC (1973) Chondroblastoma of bone. A critical review. Clin Orthop Relat Res 95:300–312PubMedCrossRef

39.

Marcove RC, Miké V, Hutter RV et al (1972) Chondrosarcoma of the pelvis and upper end of the femur. An analysis of factors influencing survival time in one hundred and thirteen cases. J Bone Joint Surg Am 54:561–572PubMed

40.

Marcove RC, Abou Zahr K, Huvos AG et al (1984) Cryosurgery in osteogenic sarcoma: report of three cases. Compr Ther 10:52–60PubMed

41.

Tsuchiya H, Wan SL, Sakayama K et al (2005) Reconstruction using an autograft containing tumour treated by liquid nitrogen. J Bone Joint Surg Br 87:218–225PubMed

42.

Tsuchiya H, Nishida H, Srisawat P et al (2010) Pedicle frozen autograft reconstruction in malignant bone tumors. J Orthop Sci 15:340–349PubMedCrossRef

43.

Yantorno C, Soanes WA, Gonder MJ et al (1967) Studies in cryoimmunology. I. The production of antibodies to urogenital tissue in consequence of freezing treatment. Immunology 12:395–410PubMed

44.

Shulman S, Brandt EJ, Yantorno C (1968) Studies in cryo-immunology. II. Tissue and species specificity of the autoantibody response and comparison with iso-immunization. Immunology 14:149–158PubMed

45.

Ablin RJ (1972) Cryoimmunotherapy. Br Med J 3:476PubMedCrossRef

46.

Soanes WA, Gonder MJ, Ablin RJ (1970) A possible immuno-cryothermic response in prostatic cancer. Clin Radiol 21:253–255PubMedCrossRef

47.

Neel HB III, Ketcham AS, Hammond WG (1973) Experimental evaluation of in situ oncocide for primary tumor therapy: comparison of tumor-specific immunity after complete excision, cryonecrosis and ligation. Laryngoscope 83:376–387PubMedCrossRef

48.

Bagley DH, Faraci RP, Marrone JC et al (1974) Lymphocyte mediated cytotoxicity after cryosurgery of a murine sarcoma. J Surg Res 17:404–406PubMedCrossRef

49.

Misao A, Sakata K, Saji S et al (1981) Late appearance of resistance to tumor rechallenge following cryosurgery. A study in an experimental mammary tumor of the rat. Cryobiology 18:386–389PubMedCrossRef

50.

Joosten JJ, Muijen GN, Wobbes T et al (2001) In vivo destruction of tumor tissue by cryoablation can induce inhibition of secondary tumor growth: an experimental study. Cryobiology 42:49–58PubMedCrossRef

51.

Sabel MS, Nehs MA, Su G et al (2005) Immunologic response to cryoablation of breast cancer. Breast Cancer Res Treat 90:97–104PubMedCrossRef

52.

Steinman RM (2003) Some interfaces of dendritic cell biology. APMIS 111:675–697PubMedCrossRef

53.

den Brok MH, Sutmuller RP, Nierkens S et al (2006) Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity. Br J Cancer 95:896–905CrossRef

54.

Urano M, Tanaka C, Sugiyama Y et al (2003) Anti-tumor effects of residual tumor after cryo-ablation: the combined effect of residual tumor and a protein-bound polysaccharide on multiple liver metastases in a murine model. Cryobiology 46:238–245PubMedCrossRef

55.

Lubaroff DM, Reynolds CM, Canfield L (1981) Immunologic aspects of the prostate. Prostate 23:233–248CrossRef

56.

Udagawa M, Saito CK, Hasegawa G et al (2006) Enhancement of immunologic tumor regression by intra-tumoral administration of dendritic cells in combination with cryoablative tumor pretreatment and bacillus Calmette–Guerin cell wall skeleton stimulation. Clin Cancer Res 12:7465–7475PubMedCrossRef

57.

Machlenkin A, Goldberger O, Tirosh B et al (2005) Combined dendritic cell cryosurgery of tumor induces systemic antimetastatic immunity. Clin Cancer Res 11:4955–4961PubMedCrossRef

58.

Osada S, Imai H, Tomita H et al (2007) Serum cytokine levels in response to hepatic cryoablation. J Surg Oncol 95:491–498PubMedCrossRef

59.

Nishida H, Tsuchiya H, Tomita K (2008) Re-implantation of tumour tissue treated by cryotreatment with liquid nitrogen induces anti-tumour activity against murine osteosarcoma. J Bone Joint Surg Br 90:1249–1255PubMedCrossRef

60.

Kawano M, Nishida H, Nakamoto Y et al (2010) Cryoimmunologic antitumor effects enhanced by dendritic cells in osteosarcoma. Clin Orthop Relat Res 468:1373–1383PubMedCrossRef

Title: Cryoimmunology for malignant bone and soft-tissue tumors
Authors: Hideji Nishida
Norio Yamamoto
Yoshikazu Tanzawa
Hiroyuki Tsuchiya
Publication date: 01-04-2011
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 2/2011
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-011-0218-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2011

Full-thickness chest-wall resection followed by thorax reconstruction for recurrent malignant phyllodes tumor

Announcing our new journal: International Cancer Conference Journal (ICCJ)

Questionnaire survey of the current status of radical trachelectomy in Japan

Inhibitory effects of dietary glucosylceramides on squamous cell carcinoma of the head and neck in NOD/SCID mice

Expression of thrombospondin-1 and Ski are prognostic factors in advanced gastric cancer

Hepatic resection with or without adjuvant iodine-131-lipiodol for hepatocellular carcinoma: a comparative analysis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer